GSK · Pharma and healthcare · one day
GSK (GSK): news on Thursday 12 November 2026
News from the 24 hours to Thursday morning, 12 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by GSK's patent wins against Pfizer and BioNTech over COVID vaccine technology, plus a settlement with Moderna. Share price commentary was slightly negative, with a minor dip and underperformance against the market.
What drove it
- patent wins against Pfizer/BioNTech
- Moderna settlement
- share price dip
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 6 Nov | +4.5 | 8 |
| Sat 7 Nov | +4.5 | 17 |
| Sun 8 Nov | +5.7 | 2 |
| Mon 9 Nov | −3.3 | 3 |
| Tue 10 Nov | +6.3 | 13 |
| Wed 11 Nov | +4.5 | 6 |
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
7 stories · 12 headlines · strongest first
Pharma and healthcare on 12 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK range-bound share price commentary −0.54 headlines today · Pieces discuss GSK's range-bound trend and momentum. | ||
| −2.5 | Shares lagged the wider market on the day. | |
| +0.3 | Generic interest piece with no concrete news. | |
| 0.0 | Technical commentary describing sideways share trading. | |
| 0.0 | Vague technical commentary on share momentum. | |
| GSK wins UPC injunction against Pfizer and BioNTech +8.72 headlines today · 5 in all · GSK won a 36-country UPC injunction over COVID vaccine patents. | ||
| +10.0 | Injunction covering many countries strengthens its patent position against rivals. | |
| +9.2 | Won patent ruling against two major vaccine rivals. | |
| GSK has two investor conferences coming up +2.72 headlines today · 7 in all, since 9 November · Pieces say GSK's stock focuses on pipeline after a UBS conference. | ||
| −1.7 | Small share price dip with focus on upcoming pipeline events. | |
| +0.8 | Pipeline emphasis continues following investor conference appearance. | |
| Moderna and GSK resolve dispute over vaccine patents +5.71 headline today · 11 in all, since 7 November · GSK and Moderna settled their cross-border patent dispute. | ||
| +4.2 | Patent dispute with Moderna resolved, removing legal uncertainty. | |
| Council leader discusses GSK Stevenage site +2.51 headline today · Stevenage council leader discussed interest in the GSK site. | ||
| +2.5 | Local council comments on interest in its Stevenage site. | |
| GSK hires Roy Jakobs, who leads Philips +1.71 headline today · GSK is reported to have hired Philips chief Roy Jakobs. | ||
| +1.7 | Appointment of experienced executive from Philips to a senior role. | |
| Deutsche Bank keeps Hold on GSK 0.01 headline today · Deutsche Bank maintained its Hold rating. | ||
| 0.0 | Broker keeps neutral rating, no change in stance.} | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.